About
Approach
Investment Model
Investment Scope
Our approach
Team
Managing Partner
Partners
Our team
Portfolio
News
Connect
Pages
Pages
Home
About
Blog
Blog Post
Contact
Portfolio
Investors
Investor Single
Shop
Shop Single
Utility Pages
Start Here
Style Guide
404 Not Found
Password Protected
Licenses
Changelog
Browse More Templates
pharmaphorum – BIO‑Europe Spring 2026: In conversation with Marjorie Sidhoum, Vice President of Business Development and Corporate Communications at Kainova Therapeutics
Article Date
March 26, 2026
This article is featured on another website.
Go to article
Related posts
Browse all articles
July 14, 2026
Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate
July 14, 2026
Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate
August 13, 2026
The Oligodendrocyte Advantage
August 13, 2026
The Oligodendrocyte Advantage